Tarcocimab achieved an extended ocular half-life of >20 days in 45% of sampled patients from the Phase 1b Study Each line represents one individual patient from the Phase 1b study of tarcocimab in patients with wet AMD, DME and RVO. N= 47 patients, all received an intravitreal injection of 5mg tarcocimab clinical formulation on day 1. *Mean and standard deviations are plotted, though SDs are not visible due to small magnitude All Patients (n=47) Weeks Tarcocimab aqueous humor concentration (ng/ml) t1/2 = 6.1 days t1/2 = 10.1 days t1/2 = 16.9 days t1/2 = 27.5 days Select Individual Patients * Weeks 12 16 20 24 1 10 100 1000 10000 100000 19% 36% 45% Patients Ocular t½ Distribution (N=47) >20 Days 11-20 Days ≤11 Days 12 16 20 24 1 10 100 1000 10000 100000 t1/2 = 39.8 days 21